Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Beam Therapeutics Inc

BEAM
Current price
29.56 USD +0.14 USD (+0.48%)
Last closed 29.57 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 410 076 160 USD
Yield for 12 month -33.38 %
Week
Month
Year
BEAM
21.11.2021 - 28.11.2021

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. Address: 238 Main Street, Cambridge, MA, United States, 02142

Analytics

WallStreet Target Price

53.69 USD

P/E ratio

Dividend Yield

Current Year

+60 920 000 USD

Last Year

+51 844 000 USD

Current Quarter

+17 193 000 USD

Last Quarter

+20 116 000 USD

Current Year

+60 920 000 USD

Last Year

+51 844 000 USD

Current Quarter

+17 193 000 USD

Last Quarter

+20 116 000 USD

Key Figures BEAM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -379 734 016 USD
Operating Margin TTM -629.72 %
PE Ratio
Return On Assets TTM -18.86 %
PEG Ratio
Return On Equity TTM -38.14 %
Wall Street Target Price 53.69 USD
Revenue TTM 81 554 000 USD
Book Value 10.09 USD
Revenue Per Share TTM 1.09 USD
Dividend Share
Quarterly Revenue Growth YOY 8.8 %
Dividend Yield
Gross Profit TTM -250 674 000 USD
Earnings Share -4.17 USD
Diluted Eps TTM -4.17 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BEAM

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BEAM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation BEAM

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 19.2468
Price Sales TTM 29.5519
Enterprise Value EBITDA -4.1336
Price Book MRQ 3.0972

Financials BEAM

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BEAM

For 52 weeks

16.95 USD 51.6 USD
50 Day MA 23.38 USD
Shares Short Prior Month 14 452 854
200 Day MA 29.14 USD
Short Ratio 8.12
Shares Short 13 826 016
Short Percent 21.51 %